Why Compare Semaglutide Wegovy Against Mounjaro?
Semaglutide Wegovy vs Mounjaro: Mechanism Differences
Understanding how semaglutide Wegovy compares to Mounjaro begins with their distinct mechanisms of action. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone, reducing appetite and promoting satiety after smaller meals. Mounjaro, containing tirzepatide, targets both GLP-1 and GIP receptors, offering a dual-hormone approach to weight management. Both are prescription-only medicines requiring clinical assessment, but this fundamental difference may influence which treatment your prescriber recommends based on your metabolic profile.
The practical implications of choosing semaglutide Wegovy versus Mounjaro extend beyond mechanism to real-world convenience factors. Wegovy follows a structured 5-dose escalation schedule (0.25mg to 2.4mg maintenance), whilst Mounjaro progresses through 6 doses (2.5mg to 15mg maintenance). Your prescriber will consider factors like your tolerance to gastrointestinal side effects, previous weight management attempts, and any concurrent medical conditions when determining whether semaglutide Wegovy or Mounjaro better suits your individual circumstances.
Semaglutide Wegovy Pricing vs Mounjaro Cost Comparison
Cost transparency remains crucial when comparing semaglutide Wegovy to Mounjaro, particularly as both represent long-term treatment commitments. Our Wegovy pricing starts at £79.99 for the 0.25mg starter dose, escalating to £209.99 for the 2.4mg maintenance dose, with new customers applying code FIRST40 at checkout to reach these final prices. Mounjaro pricing follows a similar structure, with costs varying across its 2.5mg to 15mg dose range. Both treatments require several months of dose escalation, making bundle options particularly valuable for treatment continuity.
Our Getting Started bundles provide structured progression through either semaglutide Wegovy or Mounjaro dose schedules, with options like the Intro Duo (Wegovy 0.25mg & 0.5mg) at £169.99. For patients reaching maintenance doses, our Consistency bundles ensure uninterrupted supply, such as Consistency 2.4mg (×2 Wegovy pens) at £419.99. Returning customers benefit from code DOSE25 applied at checkout, whilst the convenience of bundled delivery reduces the administrative burden of monthly prescription renewals across either treatment pathway.
Clinical Evidence: STEP Trials vs SURMOUNT Studies
The clinical foundation supporting semaglutide Wegovy derives primarily from the landmark STEP trial programme, with STEP 1 demonstrating approximately 15% average weight loss at 68 weeks when combined with lifestyle interventions (Wilding et al., NEJM, 2021). These studies established Wegovy's efficacy across diverse patient populations, including those with type 2 diabetes and varying BMI ranges. The SELECT cardiovascular outcomes trial further reinforced semaglutide's benefits, showing a 20% reduction in major cardiovascular events.
Mounjaro's evidence base stems from the SURMOUNT trial series, which evaluated tirzepatide's dual GIP/GLP-1 approach in weight management contexts. Whilst both programmes demonstrate substantial weight loss potential, direct head-to-head comparisons remain limited due to different trial designs and patient populations. Your prescriber will interpret this evidence within your specific clinical context, considering factors like cardiovascular risk, diabetes status, and previous weight management outcomes when recommending between semaglutide Wegovy and Mounjaro.
How Semaglutide Wegovy Works in Your Body
Semaglutide Wegovy functions as a GLP-1 receptor agonist, essentially mimicking a hormone naturally produced in your intestines when you eat. This mechanism triggers several coordinated responses: it slows gastric emptying, meaning food stays in your stomach longer, promoting feelings of fullness after smaller portions. Simultaneously, semaglutide acts on appetite centres in your brain, potentially reducing food cravings and the psychological drive to eat between meals. The once-weekly injection schedule helps maintain consistent hormone levels, supporting sustained appetite control throughout your treatment journey. These effects work alongside a reduced-calorie diet and increased physical activity to support your weight management goals. The 2.4mg maintenance dose represents the optimal balance between efficacy and tolerability for most patients, though individual responses vary.
Ordering Semaglutide Wegovy Through EverydayMeds
Accessing semaglutide Wegovy begins with our streamlined 3-minute online clinical assessment, designed to gather essential medical history and current health status information. Your responses undergo review by our qualified prescribers, typically within 3 working days (express 24-hour review available), who determine your suitability for Wegovy treatment and recommend appropriate starting doses. Once approved, your prescription enters our cold-chain delivery system, ensuring temperature-controlled transport that maintains semaglutide's stability from our GPhC-registered pharmacy (#9012878) directly to your door. Next-day delivery scheduling accommodates your availability, with discrete packaging protecting your privacy. This process applies equally to Mounjaro orders, allowing your prescriber flexibility to recommend the most clinically appropriate treatment based on your individual assessment outcomes.
Storage and Practical Considerations for Semaglutide Wegovy
Proper storage significantly impacts semaglutide Wegovy's effectiveness and represents a key practical advantage over Mounjaro. Unopened Wegovy pens require refrigeration at 2-8°C, but once removed from the fridge, they remain stable for up to 6 weeks at room temperature below 30°C, compared to Mounjaro's 21-day room temperature limit. This storage flexibility proves particularly valuable for frequent travelers or those with unpredictable schedules. The FlexTouch pen design simplifies weekly injections, with clear dosing windows and built-in safety features. Dose escalation follows a mandatory schedule—starting at 0.25mg and increasing monthly until reaching the 2.4mg maintenance dose—with each transition allowing your body to adapt gradually and minimising gastrointestinal side effects.
Semaglutide Wegovy vs Mounjaro: Treatment Duration Considerations
Long-term treatment planning distinguishes successful weight management from short-term interventions, making the choice between semaglutide Wegovy and Mounjaro particularly significant. Both medications function as chronic treatments rather than temporary solutions, with clinical evidence supporting sustained use for ongoing weight maintenance. The STEP 1 extension study revealed that patients regained approximately two-thirds of their weight loss within one year of discontinuing semaglutide, highlighting the importance of viewing either treatment as a long-term commitment. Your prescriber will discuss realistic expectations and develop a comprehensive plan that may include periodic treatment reviews and lifestyle support.
Cost considerations over extended treatment periods favour careful initial selection between semaglutide Wegovy and Mounjaro. Maintenance phase pricing represents the majority of your long-term investment, with Wegovy's 2.4mg dose at £209.99 per pen requiring comparison against Mounjaro's higher-dose maintenance costs. Our bundle pricing structures acknowledge this reality, offering options like the Ultimate Stability Trio (three 2.4mg Wegovy pens) at £649.99, providing three months of maintenance supply through a single order and delivery process.
Making Your Choice: Semaglutide Wegovy or Mounjaro
The decision between semaglutide Wegovy and Mounjaro ultimately rests with your prescriber's clinical judgement, informed by your medical history, current medications, and individual risk factors. Both represent evidence-based approaches to weight management, each with distinct advantages depending on your circumstances. EverydayMeds' unique position offering both treatments ensures your access isn't limited by pharmacy inventory or supplier relationships. Your clinical assessment responses will guide our prescribers toward the most appropriate recommendation, whether that's semaglutide Wegovy's proven GLP-1 approach or Mounjaro's dual-hormone mechanism. Remember that successful weight management extends beyond medication choice to encompass dietary changes, physical activity increases, and ongoing clinical monitoring. Start your assessment today using code FIRST40 for new customers or DOSE25 for returning patients, with both discount codes applied automatically at checkout to reach our competitive pricing. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your clinical assessment and discover whether semaglutide Wegovy or Mounjaro aligns better with your weight management goals.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
